Design Therapeutics Competitors and Similar CompaniesClear all

Design Therapeutics's competitors and similar companies include Abliva, Y-mAbs Therapeutics and Prevail Therapeutics.

	Design Therapeutics Design Therapeutics is a biopharmaceutical company engaged the research and development of small-molecule gene targeted chimera therapeutic candidates.	Abliva Abliva is a biotech company that discovers and develops medicines for the treatment of mitochondrial disease.	Y-mAbs Therapeutics Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets.	Prevail Therapeutics Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease.
Founding Date	Founding Date 2017	Founding Date 2000	Founding Date 2014	Founding Date 2017
Type	Type Public	Type Subsidiary	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma therapy	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma therapy	Tags Healthcare biotech clinical research drug development pharma therapy
Locations	Locations Carlsbad, US HQ	Locations Lund, SE HQ	Locations New York, US HQ Copenhagen, DK Nutley, US	Locations New York, US HQ
Employees	Employees 54	Employees 950% increase	Employees 3239% increase	Employees 489% increase
Valuation ($)	Valuation ($) 313.1 m	Valuation ($) N/A	Valuation ($) 657 m	Valuation ($) 787.7 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $87.7m (FY, 2024)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $15m (FY, 2024)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit kr497k (FY, 2024)	Gross profit $72.7m (FY, 2024)	Gross profit N/A
Net income	Net income ($69.8m) (FY, 2025)	Net income (kr90m) (FY, 2024)	Net income ($29.7m) (FY, 2024)	Net income ($63.2m) (FY, 2019)
Funding
Total funding raised	Total funding raised $ 45m	Total funding raised $ 10.8m	Total funding raised $ 80m	Total funding raised $ 125m